[關(guān)鍵詞]
[摘要]
目的 觀察丹紅注射液聯(lián)合奧扎格雷鈉對老年性腦梗死合并高血壓病的臨床療效。方法 將160例腦梗死合并高血壓病老年患者隨機分為對照組和觀察組各80例,對照組給予奧扎格雷鈉160 mg,每天1次;觀察組在對照組基礎(chǔ)上給予丹紅注射液20 mL,每天1次。2周為1個療程。觀察兩組臨床療效,比較治療前后臨床神經(jīng)功能缺損程度評分(NDS)、Barthel指數(shù)評定量表(BI)、血壓以及不良反應。結(jié)果 觀察組總有效率為93.75%,對照組總有效率為75.00%,觀察組總有效率顯著高于對照組,差異有統(tǒng)計學意義(P<0.05)。治療前,觀察組NDS評分為(24.01±7.61)分,BI評分為(38.14±6.42)分,對照組NDS評分為(24.08±7.93)分,BI評分為(38.45±8.02)分,兩組治療前NDS及BI比較,差異無統(tǒng)計學意義;治療后,觀察組NDS評分為(13.81±3.91)分,BI評分為(59.11±7.12)分,對照組NDS評分為(15.50±4.32)分,BI評分為(50.92±6.48)分,兩組治療后NDS及BI均明顯優(yōu)于治療前,差異有統(tǒng)計學意義(P<0.05)。且治療后觀察組NDS及BI均明顯優(yōu)于對照組,差異有統(tǒng)計學意義(P<0.05)。治療前,觀察組患者平均收縮壓(SBP)為(165.0±6.8)mmHg,平均舒張壓(DBP)為(101.0±5.9)mmHg,對照組患者SBP(167.0±7.6)mmHg,DBP(102.0±6.6)mmHg;治療后,觀察組患者SBP(138.0±7.6)mmHg,DBP(78.0±6.7)mmHg,對照組患者SBP(135.0±8.1)mmHg,DBP(80.0±7.2)mmHg,各組治療前后SBP和DBP比較,差異均有統(tǒng)計學意義(P<0.05),但兩組之間差異無統(tǒng)計學意義。兩組患者不良反應比較差異無統(tǒng)計學意義。結(jié)論 奧扎格雷鈉聯(lián)合丹紅注射液對老年腦梗死合并高血壓病臨床療效明顯優(yōu)于單用奧扎格雷鈉,且無嚴重不良反應,值得臨床推廣應用。
[Key word]
[Abstract]
Objective To observe the curative effect of Sodium Ozagrel combined with Danhong Injection in the treatment of senile cerebral infarction with hypertension. Methods We selected 160 cases of senile cerebral infarction with hypertension and the patients were randomly divided into control group and observation group, 80 cases in each group. The patients in control group were given Sodium Ozagrel (160 mg), once daily, while the patients in observation group were treated with sodium ozagrel (160 mg) combined with Danhong Injection (20 mL), once daily, two weeks for a course of treatment. The cinical effects of the two groups were observed after a course of treatment. NDS, BI, blood pressure, and adverse reactions were compared before and after treatment. Results The total effective rates of observation group and control group were 93.75% and 75%. The total effective rate in the observation group was significantly higher than that in the control group (P<0.05). Before treatment, the NDS score of observation group was (24.01±7.61), the BI score was (38.14±6.42), the NDS score of the control group was (24.08±7.93), the BI score was (38.45±8.02). The difference was not statistically significant. After treatment, the NDS score of the observation group was (13.81±3.91), the BI score was (59.11±7.12), the NDS score of the control group was (15.50±4.32), the BI score was (50.92±6.48). After treatment, the BI and NDS in the observation group were significantly better than those in the control group (P<0.05). After treatment, BI and NDS of two groups were significantly better than those before treatment (P<0.05). Before treatment, the average systolic blood pressure (SBP) of observation group was (165.0±6.8) mmHg and mean diastolic blood pressure (DBP) was (101.0±5.9) mmHg, SBP of control group was (167.0±7.6) mmHg, DBP was (102.0±6.6) mmHg; after treatment, the observation groups of patients with SBP (138.0±7.6) mmHg, DBP (78.0±6.7) mmHg, control group patients with SBP (135.0±8.1) mmHg, DBP (80.0±7.2) mmHg, differences before and after the treatment in the same group were statistically significant (P<0.05), but the difference between the two groups has no statistical significance. There was no significant difference in adverse reactions between the two groups. Conclusion Sodium Ozagrel combined with Danhong Injection has better effect for treating senile cerebral infarction with hypertension and without any toxic and serious side effect. It is worthy of promotion in clinic.
[中圖分類號]
[基金項目]